Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

4.210 +0.080 (+1.94%)
Streaming Delayed Price Updated: 11:11 AM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
7 Growth Stocks to Buy for Under $5 for Massive Gains ↗
Although growth stocks under $5 are inherently risky and unpredictable, their very nature also facilitates robust upside potential. 
Via InvestorPlace
News headline image
Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
A Preview Of ADC Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
ADC Therapeutics - Time For A Turn-Around? ↗
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. 
Via Talk Markets
News headline image
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget ↗
Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy. 
Via InvestorPlace
News headline image
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗
ADCT stock results show that ADC Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
Medifast Reports Mixed Results, Joins Coursera, Chegg And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
Dollar Tree Reports Weak Earnings, Joins Tesla, Arcos Dorados And Other Big Stocks Moving Lower On Wednesday ↗
U.S. stocks were mixed, with the Dow Jones index surging more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
Earnings Scheduled For March 13, 2024 ↗
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
Via Benzinga
News headline image
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
From ADC Therapeutics SA
Via GlobeNewswire
News headline image
Alaska Air To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.